Because of the high case fatality rate, the ability to spread easily by human-to-human contact, and the potential for aerosol release, Lassa is classified as a BSL-4 (bio safety level 4 agent) and is included on the NIAID Category A select agents list of potential bio-terrorism threats.
"Vybion is delighted to use ProCode to define epitopes on viral antigens that may not be triggered by the immune system and help to define critical regions of these viruses for function, neutralization and potential vaccine development," said Vybion CEO Lee Henderson, Ph.D. These epitopes will be structurally mapped by Erica Ollmann Saphire, Ph.D., of The Scripps Research Institute.
Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine, added, "We have been very pleased with the results of our development effort over the past five years. The diagnostic products have shown to be remarkably effective in clinical settings in Africa and will have a meaningful impact on the healthcare in that part of the world, but will also fill a critical gap in bioterrorism defense. Now under the new NIH award, we will move to the next level allowing us to better treat the disease, or ultimately prevent it altogether."
Dr. Garry stated that the group intends to expand this program to address ot
|SOURCE Corgenix Medical Corporation|
Copyright©2010 PR Newswire.
All rights reserved